To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.

A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing TA103 and the placebo control in the treatment of tinea pedis.

Inclusion Criteria:

• Healthy male or non pregnant female aged ≥ 18 years
• Subjects must have provided IRB approved written informed consent
• Subjects must have clinical diagnosis of interdigital tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin).

Exclusion Criteria:

• Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
• Subjects with a history of hypersensitivity or allergy to any of the study medication ingredients and its excipients.
• Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.